Health Care

OptimizeRx: how its tech‑driven platform delivers big savings on prescriptions and fuels growth in the booming digital health sector.

Galderma Group AG

NurExone Biologic Inc. tackles patent tightening and rapid Asian approval pathways to protect its spinal‑cord injury treatments, staying ahead in the biotech race.

Halozyme Therapeutics: Explore how its hyaluronidase platform powers next‑gen oncology and drug‑delivery breakthroughs, and why the $8.1 B biotech stock could be poised for growth.

Nutra Pharma Corp’s low $0.0001 stock, $7,160 market cap, and negative P/E signal major financial risks, raising investor doubts about its drug‑innovation plans.

SiNtx Technologies Inc.: Small‑cap biomaterial medical devices, $9.89 M market cap, negative P/E, growth‑stage focus on silicon‑nitride spinal and joint implants—track FDA approvals and earnings for upside.

Cuprina Holdings Cayman’s Nasdaq delisting battle: reverse split fails, share price crashes, investors face uncertain fate—what’s next?

Novavax’s COVID‑19 vaccine strategy hinges on an FDA advisory vote, influencing its future VLP‑based products and investor sentiment.

MDCE’s AI‑powered Melanoma Scan Beta lets users track skin images on an interactive body map, advancing AI imaging for health while staying transparent and compliant.

Pfizer’s $10.5 B oncology deals with Innovent and I‑Mab plus Lorbrena’s seven‑year CROWN data promise growth but raise milestone, regulatory and pricing risks that investors must weigh.